Abbott Laboratories Q1 2026 Earnings Call Summary
Abbott Laboratories reported Q1 2026 results in line with expectations, driven by the completion of the Exact Sciences acquisition and growth in medical devices. The company noted strong performance in Electrophysiology and Heart Failure, while Nutrition and Core Lab Diagnostics faced challenges. Full-year 2026 comparable sales growth is projected at 6.5% to 7.5%.
Topics: Acquisition Diabetes Care Earnings Call Electrophysiology Exact Sciences Acquisition Medical Device Growth Nutrition Segment